Back to Search Start Over

The prognostic role of post-induction FDG-PET in patients with follicular lymphoma: a subset analysis from the FOLL05 trial of the Fondazione Italiana Linfomi (FIL).

Authors :
Luminari, S.
Biasoli, I.
Versari, A.
Rattotti, S.
Bottelli, C.
Rusconi, C.
Merli, F.
Spina, M.
Ferreri, A. J. M.
Zinzani, P. L.
Gallamini, A.
Franceschetto, A.
Boccomini, C.
Franceschetti, S.
Salvi, F.
Raimondo, F. D.
Carella, A. M.
Micol, Q.
Balzarotti, M.
Musto, P.
Source :
Annals of Oncology. Feb2014, Vol. 25 Issue 2, p442-447. 6p. 3 Charts, 1 Graph.
Publication Year :
2014

Abstract

This subset analysis of the randomized FOLL05 trial demonstrated that post-induction PET can improve response assessment and is a strong independent prognostic tool in follicular lymphoma. Future studies should be designed to assess if a PET-driven approach could further improve outcome.Background [18F]fluorodeoxyglucose-positron emission tomography (PET) is emerging as a strong diagnostic and prognostic tool in follicular lymphoma (FL) patients. Patients and methods In a subset analysis of the FOLL05 trial (NCT00774826), we investigated the prognostic role of post-induction PET (PI-PET) scan. Patients were eligible to this study if they had a PI-PET scan carried out within 3 months from the end of induction immunochemotherapy. Progression-free survival (PFS) was the primary study end point. Results A total of 202 patients were eligible and analysed for this study. The median age was 55 years (range 33–75). Overall, PI-PET was defined as positive in 49 (24%) patients. Conventional response assessment with CT scan was substantially modified by PET: 15% (22/145) of patients considered as having a complete response (CR) after CT were considered as having partial response (PR) after PI-PET and 53% (30/57) patients considered as having a PR after CT were considered as a CR after PI-PET. With a median follow-up of 34 months, the 3-year PFS was 66% and 35%, respectively, for patients with negative and positive PI-PET (P < 0.001). At multivariate analysis, PI-PET (hazard ratio 2.57, 95% confidence interval 1.52–4.34, P < 0.001) was independent of conventional response, FLIPI and treatment arm. Also, the prognostic role of PI-PET was maintained within each FLIPI risk group. Conclusions In FL patients, PI-PET substantially modifies response assessment and is strongly predictive for the risk of progression. PET should be considered in further updates of response criteria. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
09237534
Volume :
25
Issue :
2
Database :
Academic Search Index
Journal :
Annals of Oncology
Publication Type :
Academic Journal
Accession number :
94393575
Full Text :
https://doi.org/10.1093/annonc/mdt562